Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Cost of sales by Quarter
Cost of sales — Royalty expense (CFF & third-party royalties, $M) ($M)
Vertex Pharmaceuticals Cost of sales: $271M in Q2 2026, up 1.5% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note (Segment Reporting — Significant Segment Expenses).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cost of sales — Royalty expense (CFF & third-party royalties, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 271 | +1.5% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 233 | +0.1% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 275 | +1.5% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 275 | +5.4% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 267 | +7.5% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 232 | -0.6% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 271 | – | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 261 | – | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 248 | – | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 234 | – | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2017 | Dec 31, 2017 | 0.30 | -62.5% | Form 10-K (filed 2018-02-15) ↗ |
| Q3 2017 | Sep 30, 2017 | 0.70 | -12.5% | Form 10-K (filed 2018-02-15) ↗ |
| Q2 2017 | Jun 30, 2017 | 0.70 | -36.4% | Form 10-K (filed 2018-02-15) ↗ |
| Q1 2017 | Mar 31, 2017 | 0.80 | -11.1% | Form 10-K (filed 2018-02-15) ↗ |
| Q4 2016 | Dec 31, 2016 | 0.80 | -38.5% | Form 10-K (filed 2018-02-15) ↗ |
| Q3 2016 | Sep 30, 2016 | 0.80 | -52.9% | Form 10-K (filed 2018-02-15) ↗ |
| Q2 2016 | Jun 30, 2016 | 1.10 | -21.4% | Form 10-K (filed 2018-02-15) ↗ |
| Q1 2016 | Mar 31, 2016 | 0.90 | -69.0% | Form 10-K (filed 2018-02-15) ↗ |
| Q4 2015 | Dec 31, 2015 | 1.30 | – | Form 10-K (filed 2017-02-23) ↗ |
| Q3 2015 | Sep 30, 2015 | 1.70 | – | Form 10-K (filed 2017-02-23) ↗ |
| Q2 2015 | Jun 30, 2015 | 1.40 | – | Form 10-K (filed 2017-02-23) ↗ |
| Q1 2015 | Mar 31, 2015 | 2.90 | – | Form 10-K (filed 2017-02-23) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Cost of sales ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/seg-cogs-royalty
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.